Mitsuyama Yoshinobu, Shiba Hiroaki, Haruki Koichiro, Fujiwara Yuki, Furukawa Kenei, Iida Tomonori, Hayashi Takenori, Ogawa Masaichi, Ishida Yuichi, Misawa Takeyuki, Kashiwagi Hideyuki, Yanaga Katsuhiko
Department of Surgery, Jikei University School of Medicine, Tokyo 105-8461, Japan.
Oncol Lett. 2012 Apr 1;3(4):767-771. doi: 10.3892/ol.2012.574. Epub 2012 Jan 18.
No evidence currently exists to demonstrate the prognostic value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in patients with unresectable colorectal cancer liver metastases (CRLM). Therefore, we retrospectively investigated the correlation between serum CEA and CA19-9 levels and overall survival in patients with unresectable CRLM. The study involved 40 patients who were diagnosed with unresectable CRLM between March 2000 and August 2010 at Jikei University Hospital, Japan. We retrospectively investigated the correlation between patient characteristics, including serum CEA and CA19-9 levels, and overall survival using univariate and multivariate analyses. In the univariate analysis, the absence of primary tumor resection (p=0.0161), the absence of systemic chemotherapy (p=0.0119), serum CEA ≥100 ng/ml (p=0.0148) and CA19-9 ≥100 U/ml (p<0.0001) were significant predictors of poor survival. In the multivariate analysis, the absence of systemic chemotherapy (p=0.0356), serum CEA ≥100 ng/ml (p=0.0079) and CA19-9 ≥100 U/ml (p=0.0002) were independent predictors. Serum CEA and CA19-9 levels are therefore independent prognostic predictors of survival in patients with unresectable CRLM.
目前尚无证据表明血清癌胚抗原(CEA)和糖类抗原19-9(CA19-9)对无法切除的结直肠癌肝转移(CRLM)患者具有预后价值。因此,我们回顾性研究了血清CEA和CA19-9水平与无法切除的CRLM患者总生存期之间的相关性。该研究纳入了2000年3月至2010年8月期间在日本慈惠会医科大学医院被诊断为无法切除的CRLM的40例患者。我们使用单因素和多因素分析回顾性研究了包括血清CEA和CA19-9水平在内的患者特征与总生存期之间的相关性。在单因素分析中,未进行原发肿瘤切除(p = 0.0161)、未进行全身化疗(p = 0.0119)、血清CEA≥100 ng/ml(p = 0.0148)和CA19-9≥100 U/ml(p<0.0001)是生存不良的显著预测因素。在多因素分析中,未进行全身化疗(p = 0.035)、血清CEA≥100 ng/ml(p = 0.0079)和CA19-9≥100 U/ml(p = 0.0002)是独立预测因素。因此,血清CEA和CA19-9水平是无法切除的CRLM患者生存的独立预后预测因素。